Champions Oncology Swings to Loss Amid Rising R&D Costs

TL;DR

**CSBR's Q1 loss and soaring R&D are a red flag; they're burning cash without immediate revenue upside, making it a risky bet.**

AI Summary

CHAMPIONS ONCOLOGY, INC. reported a net loss of $466,000 for the three months ended July 31, 2025, a significant decline from the net income of $1,313,000 in the same period last year. Oncology revenue slightly decreased to $13,995,000 from $14,061,000 year-over-year. Total costs and operating expenses surged by 14.06% to $14,522,000, up from $12,732,000, primarily driven by a 13.05% increase in cost of oncology revenue to $7,995,000 and a substantial 43.19% rise in research and development expenses to $2,082,000. The company's cash and cash equivalents increased to $10,325,000 as of July 31, 2025, from $9,785,000 on April 30, 2025, despite a negative working capital of $1.7 million. The strategic outlook emphasizes continued funding of research and development programs and new product launches, with management believing current cash and expected cash flows are adequate for the next twelve months.

Why It Matters

This shift from profit to loss, driven by increased R&D and operating costs, signals a critical juncture for CHAMPIONS ONCOLOGY. Investors should scrutinize whether these elevated expenses will translate into future revenue growth and competitive advantage in the oncology drug discovery market, especially against larger, well-funded competitors. Employees might face pressure if profitability doesn't improve, while customers could benefit from enhanced service offerings if R&D investments yield innovative solutions. The broader market will watch if CSBR can effectively monetize its TumorGraft Technology Platform to justify its increased spending and regain investor confidence.

Risk Assessment

Risk Level: high — The company reported a net loss of $466,000 for the three months ended July 31, 2025, a stark contrast to the $1,313,000 net income in the prior year. This, coupled with a negative working capital of $1.7 million and a significant increase in research and development expenses by 43.19% to $2,082,000, indicates substantial financial pressure and an uncertain path to profitability.

Analyst Insight

Investors should exercise caution and closely monitor CHAMPIONS ONCOLOGY's next few quarters for signs of improved revenue generation and cost control. Consider holding off on new investments until there's clear evidence that the increased R&D spending is translating into tangible market gains and a return to profitability.

Financial Highlights

revenue

$13,995,000

operating Margin

-3.77%

total Assets

$30,546,000

total Debt

$27,008,000

net Income

-$466,000

eps

-$0.03

gross Margin

42.87%

cash Position

$10,325,000

revenue Growth

-0.43%

Revenue Breakdown

Key Numbers

• $466,000 — Net Loss (Swung from $1.313M net income in Q1 2024 to a loss in Q1 2025.)
• $13,995,000 — Oncology Revenue (Slight decrease from $14,061,000 in Q1 2024.)
• $2,082,000 — Research and Development (Increased 43.19% from $1,454,000 in Q1 2024.)
• $14,522,000 — Total Operating Expenses (Increased 14.06% from $12,732,000 in Q1 2024.)
• $1.7 million — Negative Working Capital (Indicates short-term liquidity challenges.)
• $10,325,000 — Cash and Cash Equivalents (Increased from $9,785,000 on April 30, 2025.)
• $80.4 million — Accumulated Deficit (Increased from $79.892 million on April 30, 2025.)
• $0.03 — Basic Net Loss Per Share (Compared to $0.10 basic net income per share in Q1 2024.)

Key Players & Entities

• CHAMPIONS ONCOLOGY, INC. (company) — Registrant
• $466,000 (dollar_amount) — Net loss for Q1 2025
• $1,313,000 (dollar_amount) — Net income for Q1 2024
• $13,995,000 (dollar_amount) — Oncology revenue for Q1 2025
• $14,061,000 (dollar_amount) — Oncology revenue for Q1 2024
• $14,522,000 (dollar_amount) — Total costs and operating expenses for Q1 2025
• $12,732,000 (dollar_amount) — Total costs and operating expenses for Q1 2024
• $2,082,000 (dollar_amount) — Research and development expenses for Q1 2025
• $1,454,000 (dollar_amount) — Research and development expenses for Q1 2024
• $10,325,000 (dollar_amount) — Cash and cash equivalents as of July 31, 2025

FAQ

Risk Factors

• Deterioration in Profitability [high — financial]: The company swung from a net income of $1,313,000 in the three months ended July 31, 2024, to a net loss of $466,000 for the same period in 2025. This significant decline in profitability, coupled with rising operating expenses, poses a risk to future financial stability.
• Increasing Operating Expenses [medium — financial]: Total costs and operating expenses surged by 14.06% to $14,522,000 from $12,732,000 year-over-year. This increase was driven by a 13.05% rise in the cost of oncology revenue and a substantial 43.19% increase in R&D expenses, indicating higher costs associated with revenue generation and future growth initiatives.
• Negative Working Capital [medium — financial]: The company reported negative working capital of $1.7 million as of July 31, 2025. While cash and cash equivalents increased, this negative working capital suggests potential short-term liquidity challenges if current liabilities cannot be met by current assets.
• Accumulated Deficit [medium — financial]: The accumulated deficit increased from $79,892,000 on April 30, 2025, to $80,358,000 on July 31, 2025. This ongoing deficit highlights the company's history of net losses and the need for sustained profitability to achieve positive equity.
• Dependence on R&D Investment [medium — operational]: The significant 43.19% increase in R&D expenses to $2,082,000 reflects a strategic focus on future growth. However, this heavy investment carries the risk of not yielding the expected returns, especially if new product launches are unsuccessful or market adoption is slow.
• Stable but Stagnant Revenue [low — market]: Oncology revenue saw a slight decrease of 0.43% to $13,995,000 from $14,061,000 year-over-year. While not a significant drop, the lack of growth in the core revenue stream, despite increased operating expenses, is a concern for future scalability.

Industry Context

The oncology market is characterized by high R&D investment, long development cycles, and intense competition from established pharmaceutical companies and emerging biotech firms. Companies in this sector often rely on a pipeline of innovative treatments and diagnostic tools to drive revenue growth. Regulatory hurdles and the need for extensive clinical trials are significant factors influencing market entry and success.

Regulatory Implications

As a company operating in the healthcare and biotechnology sector, Champions Oncology is subject to stringent regulations from bodies like the FDA. Compliance with evolving healthcare laws, data privacy regulations (e.g., HIPAA), and clinical trial protocols is critical. Any failure to adhere to these regulations could result in significant fines, product recalls, or reputational damage.

What Investors Should Do

1. Monitor R&D spending and pipeline progress.
2. Analyze trends in operating expenses.
3. Evaluate short-term liquidity.
4. Assess revenue growth sustainability.

Glossary

Accumulated Deficit

The total net losses of a company over its lifetime that have not been offset by net income. (Indicates the company has historically operated at a loss, with the deficit increasing in the current period.)

Working Capital

The difference between a company's current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations. (The company has negative working capital ($1.7 million), suggesting potential short-term liquidity issues.)

Cost of Oncology Revenue

The direct costs incurred in generating revenue from oncology-related products or services. (This cost increased by 13.05%, contributing significantly to the overall rise in operating expenses and the net loss.)

Research and Development (R&D) Expenses

Costs incurred by a company to develop new products or services, or to improve existing ones. (These expenses saw a substantial 43.19% increase, reflecting a strategic investment in future growth, but also contributing to the current period's net loss.)

Year-Over-Year Comparison

Compared to the prior year's period, Champions Oncology has experienced a significant shift from net income of $1,313,000 to a net loss of $466,000. While oncology revenue remained relatively stable, decreasing slightly by 0.43% to $13,995,000, total costs and operating expenses surged by 14.06%. This increase was primarily driven by a 13.05% rise in the cost of oncology revenue and a substantial 43.19% increase in R&D expenses, indicating a more challenging operating environment and increased investment in future growth.

Key Financial Figures

• $0.001 — ich Registered Common Stock, par value $0.001 per share CSBR The Nasdaq Stock Market

Filing Documents

• csbr-20250731.htm (10-Q) — 718KB
• csbrq1731202510-qex311.htm (EX-31.1) — 10KB
• csbrq1731202510-qex312.htm (EX-31.2) — 10KB
• csbrq1731202510-qex321.htm (EX-32.1) — 8KB
• 0000771856-25-000023.txt ( ) — 4901KB
• csbr-20250731.xsd (EX-101.SCH) — 35KB
• csbr-20250731_cal.xml (EX-101.CAL) — 55KB
• csbr-20250731_def.xml (EX-101.DEF) — 142KB
• csbr-20250731_lab.xml (EX-101.LAB) — 505KB
• csbr-20250731_pre.xml (EX-101.PRE) — 334KB
• csbr-20250731_htm.xml (XML) — 643KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. Condensed Consolidated Balance Sheets as of July 31, 2025 (unaudited) and April 30, 202 5 4 Unaudited Condensed Consolidated Statements of Operations for the Three Months Ended July 31, 2025 and 2024 5 Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) for the Three Months Ended July 31, 2025 and 2024 6 Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended July 31, 2025 and 2024 7 Notes to Unaudited C ondensed C onsolidated F inancial S tatements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 19

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 23

Controls and Procedures

Item 4. Controls and Procedures 23

- OTHER INFORMATION

PART II - OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 25

Risk Factors

Item 1A. Risk Factors 25

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 25

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 25

Other Information

Item 5. Other Information 25

Exhibits

Item 6. Exhibits 26 3

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements CHAMPIONS ONCOLOGY, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Dollars in Thousands) July 31, 2025 April 30, 2025 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 10,325 $ 9,785 Accounts receivable, net 9,474 11,204 Prepaid expenses and other current assets 1,215 1,369 Total current assets 21,014 22,358 Operating lease right-of-use assets, net 4,771 5,080 Property and equipment, net 4,230 4,375 Other long-term assets 196 196 Goodwill 335 335 Total assets $ 30,546 $ 32,344 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 4,845 $ 4,248 Accrued liabilities 1,801 2,556 Current portion of operating lease liabilities 1,506 1,471 Other current liability 116 135 Deferred revenue 14,430 15,443 Total current liabilities 22,698 23,853 Non-current operating lease liabilities 4,244 4,634 Other non-current liabilities 66 85 Total liabilities $ 27,008 $ 28,572 Stockholders' equity: Common stock, $ .001 par value; 200,000,000 shares authorized; 13,908,754 and 13,897,503 shares issued; and 13,788,421 and 13,777,170 outstanding as of July 31, 2025 and April 30, 2025, respectively 14 14 Treasury stock, at cost ( 708 ) ( 708 ) Additional paid-in capital 84,560 84,358 Accumulated deficit ( 80,358 ) ( 79,892 ) Total stockholders' equity attributable to Champions Oncology, Inc. 3,508 3,772 Noncontrolling interest 30 — Total stockholders' equity 3,538 3,772 Total liabilities and stockholders' equity $ 30,546 $ 32,344 The accompanying notes are an integral part of these condensed consolidated financial statements. 4 CHAMPIONS ONCOLOGY, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars in Thousands, Except Per Share Amounts) Three Months Ended July 31, 2025 2024 Oncology revenue $ 13,995 $ 14,061 Costs and operating expenses: Cost of oncology revenue 7,995 7,072 Research and development 2,082 1,454 Sales and marketing 1,855 1,679

View Full Filing

View this 10-Q filing on SEC EDGAR